Project Grant R01HL180721
Award Date 8/15/25
Completion Date 5/31/30
Dollars Obligated $415K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Indianapolis, IN 46202, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $637,126 to the Trustees of Indiana University, doing business as Indiana University Indianapolis, to conduct research on the regulatory mechanisms of neovascularization, cardiomyocyte survival, and endothelial cell-cardiomyocyte crosstalk in myocardial infarction. The project aims to elucidate the roles of novel endothelial cell- and cardiomyocyte-specific...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $715,161 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Trustees of Indiana University, doing business as Indiana University Indianapolis (IU Indianapolis), to conduct research on the epigenetic regulation of pulmonary smooth muscle cell remodeling in pulmonary hypertension. The research aims to elucidate the molecular mechanisms by which the sphingosine kinase 2 (SPHK2) enzyme contributes to vascular...
- The federal Project Grant award of $651,009 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of Iowa to investigate the role of the protein junctophilin-2 (JP2) in regulating calcium signaling in cardiac fibroblasts and its impact on cardiac fibrosis. The project aims to employ advanced molecular, physiological, and biochemical techniques, along with innovative mouse models, to elucidate the specific...
- The federal Project Grant award of $726,452 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to model intra- and inter-cellular networks involved in TRPC6-dependent cardiac fibrosis. The award aims to leverage computational methods and multi-scale experiments to better understand how TRPC6 signaling drives myofibroblast transformation and fibrosis in response to cardiac and dermal wounds. The research will be conducted by the...
- This Project Grant award, provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate a novel biotherapeutic immunocytokine (F5111-IC) for suppressing inhibitor formation in hemophilia patients. The total award amount is $1,165,276, with a project period from January 1, 2025 to November 30, 2026. The primary services under this award involve preclinical assessments of the F5111-IC treatment platform to validate...
- The federal Project Grant award of $491,029 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a novel bioengineered lymphatic regenerating platform for the treatment of breast cancer-related lymphedema. The platform utilizes an alginate mechacrylate (ALMA) hydrogel coated with an anti-fibrotic small molecule and contains programmable cell therapies to encourage lymphatic vessel regeneration and recruitment. This research...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to understand the development of lymphovenous valves (LVVs) and their role in lymphatic dysfunction in patients with congenital heart disease (CHD). The $135,204 award to Rutgers, The State University of New Jersey will fund research to determine when cells from the second heart field (SHF) contribute to LVV development and if this SHF contribution is required for...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $596,401 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Trustees of Indiana University, doing business as Indiana University Indianapolis, to conduct research on a novel long non-coding RNA called MCRL1 and its role in regulating human cardiac and hematopoietic differentiation. The research project aims to investigate how MCRL1 interacts with the Wnt/β-catenin pathway and the epigenetic...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $487,567 to Indiana University to conduct integrative genomic analysis and develop high-dimensional risk prediction models for congenital heart defects (CHDs). The research aims to identify genetic variants and biological pathways associated with CHDs, as well as build predictive models leveraging genetic, epigenetic,...
- The University of Southern California (USC) was awarded a $808,121 Project Grant by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The project aims to elucidate how lymphatic endothelial cells detect external fluid forces and convert these signals into a biological program that orchestrates lymphatic valve formation. Specifically, the research will examine the role of the mechanosensitive ion channel PIEZO1 in sensing...